Welcome to our dedicated page for Exponent SEC filings (Ticker: EXPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The EXPO SEC filings page on Stock Titan provides access to Exponent, Inc.’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed science and engineering consulting firm, Exponent uses SEC reports to present detailed information about its financial condition, operating performance, and material events. These filings complement the company’s earnings releases and offer structured data on revenues before reimbursements, operating expenses, segment performance, and non-GAAP measures such as EBITDA and EBITDAS.
Investors can use this page to locate Exponent’s periodic reports, including annual and quarterly filings that discuss its two operating segments: the engineering and other scientific segment and the environmental and health segment. These documents describe how much each segment contributes to revenues before reimbursements and provide narrative explanations of demand trends in areas such as dispute-related services, risk management projects, and regulatory consulting across industries like construction, automotive, medical devices, utilities, chemicals, transportation, and life sciences.
The EXPO filings page also highlights current reports on Form 8-K, where Exponent discloses material events. Recent 8-K filings have incorporated press releases announcing quarterly financial results, dividend declarations, and changes to share repurchase authorizations. These filings give timely insight into board decisions on capital returns and into management’s assessment of market conditions and business performance.
Stock Titan enhances access to these documents with AI-powered summaries that explain key sections in plain language, helping readers interpret complex accounting and technical terminology. Users can quickly see how Exponent’s reported metrics, segment data, and capital allocation actions fit into its broader consulting business. This makes the EXPO SEC filings page a useful starting point for understanding Exponent’s regulatory history and ongoing reporting as a professional, scientific, and technical services company.
Form 144 filed for EXPO reports a proposed sale tied to an option exercise and recent 10b5-1 plan sales. The filer exercised 4,905 common shares on 09/15/2025, paid in cash, with an aggregate market value reported as $343,595.25. The issuer's shares outstanding are listed as 50,501,135, and the proposed sale is to occur on 09/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also discloses two 10b5-1 sales by Catherine Ford Corrigan on 08/14/2025 totaling 4,896 shares with combined gross proceeds of $348,042.61. The notice includes the standard attestation regarding material nonpublic information.
Catherine Corrigan, President & CEO and Director of Exponent Inc (EXPO), reported option exercises and related stock sales on 08/14/2025. She exercised two non-qualified stock option tranches: 3,226 options at a $25.405 exercise price and 2,380 options at $29.05. Concurrent with exercise, shares were sold: 3,226 shares at $70.9347 and 1,670 shares at $71.3816; the filing states the sale was to cover the option exercise price and taxes. After these transactions her beneficial ownership of common stock was reported as 82,052 shares.
Notice of proposed sale under Rule 144 for Exponent Inc (EXPO). The filer proposes to sell 4,896 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $355,694.40. The securities are listed on NASDAQ and approximately dated for sale on 08/14/2025. The shares were acquired on 08/14/2025 by exercise of stock options from the issuer and payment was made in cash on the same date. The form states there were no securities sold in the past three months by the reporting person and includes the standard representation that the signer does not possess undisclosed material adverse information.
Joseph Sala, Group Vice President at Exponent Inc (EXPO), reported the sale of 1,595 shares of common stock on 08/12/2025 at a price of $70.6406 per share. The Form 4 discloses this Section 16 transaction and shows reported beneficial ownership of 0 shares following the sale. No derivative securities or additional transactions are listed on the form, and no explanatory detail is provided within the filing.
This Form 144 filed for Exponent Inc (EXPO) notifies of a proposed sale under Rule 144 of 1,595 common shares with an aggregate market value of $112,671.76, to be executed through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/12/2025. The filing identifies the securities as restricted stock acquired in two tranches: 833 shares on 03/12/2021 and 762 shares on 03/12/2025.
The notice reports 50,501,135 shares outstanding, making the proposed sale represent a vanishingly small portion of the company (roughly 0.003% of outstanding shares). No securities were reported sold by the filer in the past three months. The document is a routine insider sale notice and provides transparent transactional detail but no new operational or financial information about the company.
Exponent reported modest top-line growth with mixed profitability. Second-quarter revenues were $141,962,000, up 1% year-over-year, driven by higher billing rates in engineering services. Net income fell 9% to $26,553,000 and diluted EPS declined to $0.52 from $0.57, reflecting higher compensation-related costs and lower utilization.
The firm generated $43,496,000 of operating cash flow in the first six months and held $231,801,000 in cash and cash equivalents at period end. Billable hours declined 6% and utilization fell to 72%, while a large change in the fair value of deferred compensation plan assets increased other income but also raised corporate compensation expense, materially reducing operating income for the quarter. The company continued shareholder returns via $0.30 per-share quarterly dividend and increased share repurchases ($32.68M year-to-date).